Capricor Therap (CAPR) Stock Price, Quote & News

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1755

Website: www.capricor.com

Address:

10865 Road to the Cure, Suite 150, San Diego, United States

Carnagex Sep. 19 at 3:24 AM

$CAPR

1 · Reply

Nathannathan1986 Sep. 19 at 1:35 AM

$CAPR Exondys 51 (eteplirsen): Approved in 2016 for Duchenne muscular dystrophy, this drug was the center of an internal FDA civil war. The advisory panel voted 7–6 against concluding that the drug was effective. Despite their vote and fierce opposition from the FDA’s own top medical review team, senior agency leadership pushed the approval through. FDA will approve CAPR too.

1 · Reply

Nathannathan1986 Sep. 19 at 1:34 AM

$CAPR Elevidys (delandistrogene moxeparvovec): In June 2023, the FDA approved Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy. An advisory panel had narrowly voted 8–6 against recommending it for approval, arguing that clinical trials failed to meet their main goals. The FDA approved it initially for young children anyway, and later expanded its use. FDA will approve CAPR too

0 · Reply

quickaspeter Sep. 19 at 1:13 AM

$CAPR Right on…let’s go! 💥🚀💰💰💰

0 · Reply

Oddisey Sep. 18 at 10:44 PM

$CAPR Give thanks to the Power Above for a great week with CAPR I have no complaints. This cpuld have dipped to 6 or 7, but it did not. Cheers to everyone who is bullish and are holding. We got this!

0 · Reply

Stef_Gee Sep. 18 at 10:09 PM

$CAPR To make money ? That's not the name of the game in stock market ? 🤔

2 · Reply

Stef_Gee Sep. 18 at 10:05 PM

$CAPR We know the game 😏

1 · Reply

Stef_Gee Sep. 18 at 9:54 PM

$CAPR T'was a short open 🤫

0 · Reply

Stef_Gee Sep. 18 at 9:52 PM

$CAPR Yep, two completely different things (apples and oranges). FDA approving another rare disease drug doesn’t make CAPR more likely to be approved and has zero bearing on CAPR’s outcome. CAPR has to stand on its own data, trial design and FDA review You understand market 😉🤫

1 · Reply

Dash_Man Sep. 18 at 9:51 PM

$CAPR OK, options expiration is over. If logic applied here, I would expect some short covering leading up to WMS. But this is Capricor after all, so the crazy bastards will probably double down.

0 · Reply

Capricor Therapeutics, Inc. Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending September 28, 2026 Lead Plaintiff Deadline

Sep 17, 2026, 8:30 AM EDT - 1 day ago

Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress

Sep 14, 2026, 1:45 PM EDT - 4 days ago

Kaplan Fox Advises Investors of Capricor Therapeutics, Inc. (CAPR) to Contact the Firm Before the Deadline on September 28, 2026

2026-09-14T11:20:29.000Z - 4 days ago

Capricor Therapeutics upgraded to Buy from Neutral at B. Riley

Sep 11, 2026, 3:15 PM EDT - 7 days ago

Kaplan Fox Encourages Capricor Therapeutics, Inc. (CAPR) Investors Who Suffered Losses to Seek a Leadership Role Before September 28, 2026

Sep 11, 2026, 12:21 PM EDT - 7 days ago

SHAREHOLDER REMINDER: Berger Montague Reminds Capricor Therapeutics, Inc. (CAPR) Investors of the September 28, 2026 Deadline

Sep 11, 2026, 9:45 AM EDT - 7 days ago

Kaplan Fox Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to an Approaching Lead Plaintiff Deadline on September 28, 2026

Sep 9, 2026, 8:40 AM EDT - 9 days ago

LAWSUIT INVESTOR NOTICE: Investors who lost money with Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares should contact the Shareholders Foundation

Sep 7, 2026, 6:07 AM EDT - 11 days ago

Capricor Therapeutics (NASDAQ:CAPR) Shares Fall 64% Following Clinical Data Disclosure -- Investors with Losses Notified to Contact BFA Law before September 28 Deadline

Sep 4, 2026, 3:10 PM EDT - 14 days ago

Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (CAPR) to Act Ahead of the Lead Plaintiff Deadline on September 28, 2026

Sep 4, 2026, 9:30 AM EDT - 14 days ago

Kaplan Fox Notifies Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the Lead Plaintiff Deadline on September 28, 2026

Sep 2, 2026, 2:30 PM EDT - 16 days ago

Kaplan Fox Alerts Capricor Therapeutics, Inc. (CAPR) Investors to the Lead Plaintiff Deadline on September 28, 2026

Sep 2, 2026, 9:15 AM EDT - 16 days ago

Kaplan Fox Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026

Sep 2, 2026, 6:37 AM EDT - 16 days ago

$CAPR News: Capricor Therapeutics Sued for Securities Fraud Over Alleged Misrepresentations about its Clinical Data – Contact BFA Law by September 28 if You Lost Money

Sep 1, 2026, 2:15 PM EDT - 17 days ago

Kaplan Fox Urges Capricor Therapeutics, Inc. (CAPR) Investors Seeking Recovery to Contact the Firm Before September 28, 2026

2026-09-01T09:20:13.000Z - 17 days ago

Capricor Therapeutics upgraded to Overweight from Neutral at Piper Sandler

2026-09-01T09:05:12.000Z - 17 days ago

Capricor Therapeutics upgraded to Overweight from Neutral at Piper Sandler

Aug 28, 2026, 9:21 AM EDT - 21 days ago

Capricor Therapeutics, Inc. (CAPR) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Aug 26, 2026, 9:45 AM EDT - 23 days ago

Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 for a Leadership Role

Aug 25, 2026, 10:17 AM EDT - 24 days ago

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Capricor Therapeutics, Inc. Lawsuit - CAPR

2026-08-25T11:05:58.000Z - 24 days ago

Capricor Therapeutics upgraded to Outperform from Perform at Oppenheimer

2026-08-24T14:30:19.000Z - 25 days ago

Wainwright says Capricor’s regulatory risk still high after FDA PDUFA extension

Aug 24, 2026, 9:39 AM EDT - 25 days ago

US FDA extends review of Capricor's muscle disorder therapy by three months

2026-08-24T13:35:13.000Z - 25 days ago

Capricor says FDA extends action date for Deramiocel for amendment review

2026-08-24T13:35:08.000Z - 25 days ago

Capricor Therapeutics jumps 18% to $7.42 as FDA reviews Deramiocel

Aug 24, 2026, 9:30 AM EDT - 25 days ago

Kaplan Fox Advises Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Act Before the Lead Plaintiff Deadline on September 28, 2026

Aug 24, 2026, 9:25 AM EDT - 25 days ago

Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA

2026-08-21T11:50:09.000Z - 4 weeks ago

Kaos Capital urges Capricor shareholders to support immediate board meeting

Aug 20, 2026, 9:15 AM EDT - 4 weeks ago

Kaplan Fox Encourages Capricor Therapeutics, Inc. (CAPR) Investors to Contact the Firm Before the Lead Plaintiff Deadline on September 28, 2026

Aug 18, 2026, 6:17 AM EDT - 4 weeks ago

CAPR Stock News: Capricor Therapeutics Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 64% Stock Drop

2026-08-16T14:11:23.000Z - 4 weeks ago

Capricor Therapeutics reports Q2 EPS (70c), consensus (58c)

2026-08-16T14:11:12.000Z - 4 weeks ago

Capricor Therapeutics expects cash to fund operations for at least 12 months

2026-08-16T13:58:45.000Z - 4 weeks ago

Capricor Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald

2026-08-16T13:56:45.000Z - 4 weeks ago

Cantor upgrades Capricor on ‘major update’ from earnings call

Aug 14, 2026, 6:39 AM EDT - 5 weeks ago

Capricor shares skyrocket as FDA agrees to review new Duchenne drug data

Aug 13, 2026, 4:30 PM EDT - 5 weeks ago

Capricor Therapeutics Earnings Call Transcript: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 weeks ago

Capricor Therapeutics Earnings release: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 weeks ago

Capricor Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 4:05 PM EDT - 5 weeks ago

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 11, 2026, 8:30 AM EDT - 5 weeks ago

Kaplan Fox Reminds Capricor Therapeutics, Inc. (CAPR) Investors Seeking Recovery of the Lead Plaintiff Deadline on September 28, 2026

Aug 11, 2026, 7:07 AM EDT - 5 weeks ago

CAPR Investor Announcement: Capricor Therapeutics Sued on behalf of Investors to Recover Losses after Clinical Data Leads to 64% Stock Drop

Aug 10, 2026, 8:30 AM EDT - 5 weeks ago

Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13

Aug 6, 2026, 10:45 AM EDT - 6 weeks ago

Kaplan Fox Reminds Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Significant Losses to Seek a Leadership Role Before Deadline on September 28, 2026

Aug 5, 2026, 4:08 PM EDT - 6 weeks ago

Kaplan Fox Urges Investors of Capricor Therapeutics, Inc. (CAPR) with Significant Losses to Seek a Leadership Role Before September 28, 2026

Aug 4, 2026, 3:38 PM EDT - 6 weeks ago

Lowey Dannenberg, P.C. is Investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) for Potential Violations of the Federal Securities Laws

Aug 4, 2026, 12:47 PM EDT - 6 weeks ago

CAPRICOR THERAPEUTICS, INC. (CAPR) INVESTOR ALERT Investors With Large Losses in Capricor Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Aug 3, 2026, 6:36 AM EDT - 6 weeks ago

CAPR Investigation Notice: Capricor Therapeutics Hit with Securities Fraud Investigation over Clinical Data Misrepresentations – Investors Urged to Contact BFA Law

Jul 30, 2026, 10:55 AM EDT - 7 weeks ago

Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

Jul 30, 2026, 10:24 AM EDT - 7 weeks ago

CAPR SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Capricor

Jul 30, 2026, 9:30 AM EDT - 7 weeks ago

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

Jul 30, 2026, 8:06 AM EDT - 7 weeks ago

Capricor plummets after FDA panel votes against Duchenne heart disease therapy

Carnagex Sep. 19 at 3:24 AM

$CAPR

1 · Reply

Nathannathan1986 Sep. 19 at 1:35 AM

1 · Reply

Nathannathan1986 Sep. 19 at 1:34 AM

0 · Reply

quickaspeter Sep. 19 at 1:13 AM

$CAPR Right on…let’s go! 💥🚀💰💰💰

0 · Reply

Oddisey Sep. 18 at 10:44 PM

$CAPR Give thanks to the Power Above for a great week with CAPR I have no complaints. This cpuld have dipped to 6 or 7, but it did not. Cheers to everyone who is bullish and are holding. We got this!

0 · Reply

Stef_Gee Sep. 18 at 10:09 PM

$CAPR To make money ? That's not the name of the game in stock market ? 🤔

2 · Reply

Stef_Gee Sep. 18 at 10:05 PM

$CAPR We know the game 😏

1 · Reply

Stef_Gee Sep. 18 at 9:54 PM

$CAPR T'was a short open 🤫

0 · Reply

Stef_Gee Sep. 18 at 9:52 PM

1 · Reply

Dash_Man Sep. 18 at 9:51 PM

$CAPR OK, options expiration is over. If logic applied here, I would expect some short covering leading up to WMS. But this is Capricor after all, so the crazy bastards will probably double down.

0 · Reply

Stef_Gee Sep. 18 at 9:45 PM

$CAPR Sept. 29 is the deadline for investors to seek lead plaintiff status in the federal securities class action against CAPR. Capricor made misleading statements regarding changes to the HOPE-3 statistical analysis plan and the FDA’s agreement with those changes. It’s NOT an FDA decision date or a court ruling date, just the lawsuit deadline. AND also the World Muscle Society Congress starts Sept. 29 (to Oct 3) where CAPR will present Deramiocel data

0 · Reply

Wallstreetiscriminal Sep. 18 at 9:19 PM

$CAPR Hey Paul you should contact Gary. You small dick shorts can hang out! Well barely! 😂

1 · Reply

Mauismart Sep. 18 at 8:32 PM

$CAPR i couldnt resist buying more shares at 9.01. After i bought i watched the price drop to 8.97 . Then a large buyer came in for over 100k shares at the market. That put me in the green for those shares. Nice buys at the end and my 9 dollar calls are now welcoming in my account.

0 · Reply

Andromedian Sep. 18 at 8:32 PM

$CAPR Hope you took the opportunity to add today, t oh hat’s what the August move down was designed for😂

1 · Reply

Oddisey Sep. 18 at 8:27 PM

$CAPR Now 9.28 Wow!!💥💥

1 · Reply

Pinnell Sep. 18 at 8:11 PM

$CAPR

0 · Reply

ObsOlet Sep. 18 at 8:07 PM

$CAPR My current assessment regarding Thursday's news: The selection for the WMS, featuring both a late-breaking poster and an oral presentation, is truly remarkable! I find the title of the oral presentation even more interesting: "evidence to support both musculoskeletal and cardiac efficacy." Combined with the 24-month, delayed-start, and natural history data from the major amendment, this definitely inspires hope for the ongoing FDA review. The announcement that all data will be uploaded to the website is even better than a "standard" press release!

0 · Reply

Oddisey Sep. 18 at 8:03 PM

$CAPR 9.14 after close.. Monday will be epic

1 · Reply

wkee Sep. 18 at 8:02 PM

$CAPR wow what an ending large block buys !! 134,000 was scooped up somebody bought right away and that was the last at 4 o'clock

0 · Reply

etrader99 Sep. 18 at 7:55 PM

$CAPR reversing into the close

0 · Reply

longsprosper Sep. 18 at 7:51 PM

$CAPR 🥱🥱🥱🥱🥱🥱🥱🥱

0 · Reply

graywolf Sep. 18 at 7:42 PM

$CAPR looks like they are pinning it at $9 for options but I expect to see $10+ next week.

1 · Reply

Market Cap	547.67M
Revenue (ttm)	0.00
Net Income (ttm)	-105.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,253,000
Avg Vol	7,629,018
Day's Range	N/A - N/A
Shares Out	58.14M
Stochastic %K	55%
Beta	0.72
Analysts	Sell
Price Target	$23.67